Wilms Tumor Protein (WT33 or WT1) – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Wilms Tumor Protein (WT33 or WT1)- Pipeline Review, H2 2019’, provides in depth analysis on Wilms Tumor Protein (WT33 or WT1) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Wilms Tumor Protein (WT33 or WT1) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology under development targeting Wilms Tumor Protein (WT33 or WT1).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.”

Scope


– The report provides a snapshot of the global therapeutic landscape for Wilms Tumor Protein (WT33 or WT1)

– The report reviews Wilms Tumor Protein (WT33 or WT1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Wilms Tumor Protein (WT33 or WT1) targeted therapeutics and enlists all their major and minor projects

– The report assesses Wilms Tumor Protein (WT33 or WT1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Wilms Tumor Protein (WT33 or WT1) targeted therapeutics”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Wilms Tumor Protein (WT33 or WT1)Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Wilms Tumor Protein (WT33 or WT1) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

“Cue Biopharma Inc

Inovio Pharmaceuticals Inc

Scancell Holdings Plc

SELLAS Life Sciences Group Inc

Sumitomo Dainippon Pharma Co Ltd

tella Inc

Vaximm AG”

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Wilms Tumor Protein (WT33 or WT1) - Overview

Wilms Tumor Protein (WT33 or WT1) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Wilms Tumor Protein (WT33 or WT1) - Therapeutics Assessment

Assessment by Route of Administration

Assessment by Molecule Type

Wilms Tumor Protein (WT33 or WT1) - Companies Involved in Therapeutics Development

Inovio Pharmaceuticals Inc

Otsuka Holdings Co Ltd

Scancell Holdings Plc

SELLAS Life Sciences Group Inc

Sumitomo Dainippon Pharma Co Ltd

Vaximm AG

Wilms Tumor Protein (WT33 or WT1) - Drug Profiles

galinpepimut-S - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INO-5401 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OCV-501 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ombipepimut-s - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target NY-ESO-1, PRAME, MAGE-A3 and WT-1 for Acute Myeloid Leukemia and Myelodysplastic Syndrome - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target Wilm's Tumor 1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target Wilms Tumor Protein for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target WT1 for Glioblastoma Multiforme - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target WT1 for Leukemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target WT1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target WT1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target WT1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VXM-06 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Wilms Tumor Protein (WT33 or WT1) - Dormant Products

Wilms Tumor Protein (WT33 or WT1) - Discontinued Products

Wilms Tumor Protein (WT33 or WT1) - Product Development Milestones

Featured News & Press Releases

Sep 13, 2018: SELLAS Receives Orphan Medicinal Product Designation Approval by the Committee for Orphan Medicinal Products of the European Medicines Agency for Galinpepimut-S for the Treatment of Patients with Multiple Myeloma

Aug 20, 2018: Inovio doses first patient in Phase l/lla of INO-5401 and atezolizumab

Jul 20, 2018: SELLAS Receives Fast Track Designation from FDA for Galinpepimut-S for the Treatment of Patients with Multiple Myeloma

Jun 21, 2018: Inovio Announces Treatment of First Patient in Immuno-Oncology Study for Glioblastoma (GBM) with INO-5401 in Combination with Regeneron’s PD-1 Inhibitor

Jun 04, 2018: SELLAS Life Sciences Presents Interim Phase 1 Clinical Data of Galinpepimut-S (GPS) in Combination with Nivolumab to Treat Wilms Tumor 1 Positive (WT1+) Ovarian Cancer Patients at ASCO 2018

Jun 01, 2018: Boston Biomedical Highlights Presentations on Investigational Agent DSP-7888 (ombipepimut-S) at ASCO 2018

May 17, 2018: SELLAS Life Sciences to Present Phase 1/2 Clinical Data of Galinpepimut-S (GPS) in Ovarian Cancer at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

May 17, 2018: Sumitomo Dainippon Pharma announces the Clinical Data will be presented at ASCO 2018

May 09, 2018: SELLAS Life Sciences Receives FDA Orphan Drug Designation for Galinpepimut-S (GPS) for Treatment of Multiple Myeloma (MM)

Apr 25, 2018: Boston Biomedical Initiates Two Studies Evaluating WT1 Cancer Peptide Vaccine DSP-7888 (ombipepimut-S)

Mar 19, 2018: SELLAS Life Sciences Phase 2 Results for Galinpepimut-S in High-Risk Multiple Myeloma Presented at European Society for Blood and Marrow Transplantation Meeting

Feb 27, 2018: Data From SELLAS Life Sciences' Positive Phase 2 Acute Myeloid Leukemia Study Published in American Society of Hematology's Journal, Blood Advances

Jan 24, 2018: SELLAS Life Sciences Group to Present Complete Phase 2 Correlative Results for its Lead Cancer Immunotherapy Candidate, galinpepimut-S (GPS), in Treatment of Multiple Myeloma: Oral Presentation at the 2018 European Society for Blood and Marrow Transplantation Meeting

Nov 27, 2017: Inovio Pharmaceuticals SynCon TERT Cancer Immunotherapy Combined with Checkpoint Inhibitor Synergistically Shrinks Tumor and Improves Survival in Preclinical Tumor Model

Nov 01, 2017: Inovio Pharmaceuticals Initiates Immuno-Oncology Clinical Study for Glioblastoma in Combination with Regenerons PD-1 Inhibitor

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

“List of Tables

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Indications, H2 2019

Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019

Number of Products under Development by Indications, H2 2019 (Contd..2), H2 2019

Number of Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Number of Products under Investigation by Universities/Institutes, H2 2019

Products under Investigation by Universities/Institutes, H2 2019

Products under Investigation by Universities/Institutes, H2 2019 (Contd..1), H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Pipeline by Cue Biopharma Inc, H2 2019

Pipeline by Inovio Pharmaceuticals Inc, H2 2019

Pipeline by Scancell Holdings Plc, H2 2019

Pipeline by SELLAS Life Sciences Group Inc, H2 2019

Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2019

Pipeline by tella Inc, H2 2019

Pipeline by Vaximm AG, H2 2019

Dormant Products, H2 2019

Dormant Products, H2 2019 (Contd..1), H2 2019

Discontinued Products, H2 2019”

List of Figures

“List of Figures

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Top 10 Indications, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019”

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2960

Saved reports